Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Rating of “Hold” by Analysts

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been given an average recommendation of “Hold” by the twenty-three analysts that are covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $20.25.

NTLA has been the topic of several recent analyst reports. Citizens Jmp boosted their target price on Intellia Therapeutics from $28.00 to $30.00 and gave the stock a “market outperform” rating in a report on Tuesday, April 28th. Citigroup reaffirmed an “outperform” rating on shares of Intellia Therapeutics in a report on Tuesday, April 28th. Sanford C. Bernstein upped their price objective on Intellia Therapeutics from $13.00 to $17.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. William Blair raised Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a report on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Tuesday, April 21st.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd acquired a new position in Intellia Therapeutics during the 3rd quarter worth $30,000. Advisory Services Network LLC acquired a new position in Intellia Therapeutics during the 3rd quarter worth $33,000. Headlands Technologies LLC acquired a new position in Intellia Therapeutics during the 2nd quarter worth $26,000. Comerica Bank lifted its holdings in Intellia Therapeutics by 45.8% during the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after buying an additional 901 shares in the last quarter. Finally, Danske Bank A S acquired a new position in Intellia Therapeutics during the 3rd quarter worth $50,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

Shares of NTLA opened at $12.11 on Friday. The company has a market capitalization of $1.69 billion, a P/E ratio of -3.42 and a beta of 1.92. Intellia Therapeutics has a one year low of $7.95 and a one year high of $28.25. The business’s 50 day simple moving average is $13.60 and its 200-day simple moving average is $12.30.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Monday, May 11th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.11. The business had revenue of $15.05 million for the quarter, compared to the consensus estimate of $13.81 million. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.During the same period in the previous year, the business earned ($1.10) EPS. On average, sell-side analysts anticipate that Intellia Therapeutics will post -3.18 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.